Biohit and OnSite Diagnostic Labs India Pvt Ltd. to start co-operation
Biohit Oyj Press Release 2.3.2016 at 12:30 am. local time (EET)
Biohit Oyj and Onsite Diagnostic Labs India Pvt Ltd have signed a distributor agreement for the unique Biohit diagnostic portfolio in India. OnSite Diagnostic Labs India Pvt Ltd will solely focus on the marketing of Biohit's tests in India. Diagnostic tests covered by the distribution agreement include e.g.:
GastroPanel is the test for stomach health. This test is performed from a blood sample and designed for accurate diagnosis of H. pylori infection and atrophic gastritis, irrespective whether caused by H. pylori infection or autoimmune disease. This test enables to assess whether the patient is at risk for gastric or esophageal cancer, peptic ulcer disease or malabsorption of vitamin B12, calcium or iron. GastroPanel also helps identifying the patients who need further examinations. (Attachment: Additional information).
Active vitamin B12 test measures the blood levels of circulating active B12 vitamin (holotranscobalamin). Vitamin B12 deficiency can occur in seemingly healthy people, and the risk increases with age and after long-term use of proton pump inhibitors (PPIs).
Celiac Quick test measures elevated tTG IgA/G/M antibodies in serum, diagnostic to celiac disease (CD). The test contributes to substantial savings in healthcare costs, by reducing the number of unnecessary endoscopies.
Calprotectin test is used to differentiation of inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) as well as in monitoring of the treatment in IBD patients.
ColonView-FIT is a quick test for detection of fecal occult blood (FOB), used in screening of colorectal cancer. This highly sensitive test detects FOB derived from both the upper and lower gastrointestinal tract, thus facilitating the diagnosis of even small benign lesions (polyps) and cancer precursor lesions (adenomas).
CEO Jagdeep Singh, OnSite Diagnostic Labs India Pvt Ltd: ‘Our mission of preventing people becoming patients by focusing on key disease areas contributing to death rates in India and bringing advanced technologies for early diagnosis, is becoming realized by the partnership with Biohit in the gastroenterology field. Utilizing the innovative tests from the Biohit portfolio, based on advanced technology, we are making early stomach health screening more accessible and affordable for Indians everywhere.’
CEO Semi Korpela, Biohit Oyj: ‘We are very excited about the co-operation with OnSite Diagnostic Labs India Pvt Ltd, sharing our vision of the importance of early diagnosis of GI tract related diseases, and the registration in order to obtain the marketing authorization for the products has started.’
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
OnSite Diagnostic Labs India Pvt Ltd in brief
OnSite Diagnostic Labs India Pvt Ltd will market Biohit tests through its CheckMyHealth initiative. CheckMyHealth is devoted to screening, detecting and preventing the top killer diseases that affect Indians today. Together with Biohit CheckMyHealth is launching a unique portfolio of tests to help and treat potential problems before they become severe. http://checkmyhealth.com/